Therapeutic use of bone morphogenetic proteins
The invention relates to a polypeptide selected from bone morphogenetic protein 10 (BMP10), or a bone morphogenetic protein 9 (BMP9) variant lacking osteogenic activity, for use in the treatment of a vascular disease or a respiratory disease. The invention also relates to novel BMP9 variants and to pharmaceutical compositions comprising said polypeptides.
1. A vector comprising a nucleotide sequence encoding a bone morphogenetic protein 9 (BMP9) variant having endothelial cell signaling activity and lacking osteogenic activity, wherein the difference between the amino acid sequence of said BMP9 variant and the amino acid sequence of SEQ ID NO: 4 consists of a substitution selected from the group consisting of F362A, D366A, I375A, L379A, S402A, D408A, Y416A and Y418A.
2. The vector of claim 1 , wherein said vector is a viral vector, and wherein said viral vector is selected from the group consisting of a retrovirus, an adenovirus, a lentivirus, a herpes simplex virus, a vaccinia virus and an adeno-associated virus.
3. A polypeptide which is a bone morphogenetic protein 9 (BMP9) variant having endothelial cell signaling activity and lacking osteogenic activity, wherein the difference between the amino acid sequence of said BMP9 variant and the amino acid sequence of SEQ ID NO: 4 consists of a substitution selected from the group consisting of F362A, D366A, I375A, L379A, S402A, D408A, Y416A and Y418A.
4. The polypeptide of claim 3 , wherein the difference between the amino acid sequence of said BMP9 variant and the amino acid sequence of SEQ ID NO: 4 consists of the substitution Y416A.
5. A composition comprising a polypeptide which is a bone morphogenetic protein 9 (BMP9) variant having endothelial cell signaling activity and lacking osteogenic activity, wherein the difference between the amino acid sequence of said BMP9 variant and the amino acid sequence of SEQ ID NO: 4 consists of a substitution selected from the group consisting of F362A, D366A, I375A, L379A, S402A, D408A, Y416A and Y418A.
6. The composition of claim 5 , wherein the difference between the amino acid sequence of said BMP9 variant and the amino acid sequence of SEQ ID NO: 4 consists of the substitution Y416A.
7. The vector of claim 1 , wherein the difference between the amino acid sequence of said BMP9 variant and the amino acid sequence of SEQ ID NO: 4 consists of the substitution F362A.
8. The vector of claim 1 , wherein the difference between the amino acid sequence of said BMP9 variant and the amino acid sequence of SEQ ID NO: 4 consists of the substitution D366A.
9. The vector of claim 1 , wherein the difference between the amino acid sequence of said BMP9 variant and the amino acid sequence of SEQ ID NO: 4 consists of the substitution I375A.
10. The vector of claim 1 , wherein the difference between the amino acid sequence of said BMP9 variant and the amino acid sequence of SEQ ID NO: 4 consists of the substitution L379A.
11. The vector of claim 1 , wherein the difference between the amino acid sequence of said BMP9 variant and the amino acid sequence of SEQ ID NO: 4 consists of the substitution S402A.
12. The vector of claim 1 , wherein the difference between the amino acid sequence of said BMP9 variant and the amino acid sequence of SEQ ID NO: 4 consists of the substitution D408A.
13. The vector of claim 1 , wherein the difference between the amino acid sequence of said BMP9 variant and the amino acid sequence of SEQ ID NO: 4 consists of the substitution Y416A.
14. The vector of claim 1 , wherein the difference between the amino acid sequence of said BMP9 variant and the amino acid sequence of SEQ ID NO: 4 consists of the substitution Y418A.
15. The polypeptide of claim 3 , wherein the difference between the amino acid sequence of said BMP9 variant and the amino acid sequence of SEQ ID NO: 4 consists of the substitution F362A.
16. The polypeptide of claim 3 , wherein the difference between the amino acid sequence of said BMP9 variant and the amino acid sequence of SEQ ID NO: 4 consists of the substitution D366A.
17. The polypeptide of claim 3 , wherein the difference between the amino acid sequence of said BMP9 variant and the amino acid sequence of SEQ ID NO: 4 consists of the substitution I375A.
18. The polypeptide of claim 3 , wherein the difference between the amino acid sequence of said BMP9 variant and the amino acid sequence of SEQ ID NO: 4 consists of the substitution L379A.
19. The polypeptide of claim 3 , wherein the difference between the amino acid sequence of said BMP9 variant and the amino acid sequence of SEQ ID NO: 4 consists of the substitution S402A.
20. The polypeptide of claim 3 , wherein the difference between the amino acid sequence of said BMP9 variant and the amino acid sequence of SEQ ID NO: 4 consists of the substitution D408A.
21. The polypeptide of claim 3 , wherein the difference between the amino acid sequence of said BMP9 variant and the amino acid sequence of SEQ ID NO: 4 consists of the substitution Y418A.
22. The composition of claim 5 , wherein the difference between the amino acid sequence of said BMP9 variant and the amino acid sequence of SEQ ID NO: 4 consists of the substitution F362A.
23. The composition of claim 5 , wherein the difference between the amino acid sequence of said BMP9 variant and the amino acid sequence of SEQ ID NO: 4 consists of the substitution D366A.
24. The composition of claim 5 , wherein the difference between the amino acid sequence of said BMP9 variant and the amino acid sequence of SEQ ID NO: 4 consists of the substitution I375A.
25. The composition of claim 5 , wherein the difference between the amino acid sequence of said BMP9 variant and the amino acid sequence of SEQ ID NO: 4 consists of the substitution L379A.
26. The composition of claim 5 , wherein the difference between the amino acid sequence of said BMP9 variant and the amino acid sequence of SEQ ID NO: 4 consists of the substitution S402A.
27. The composition of claim 5 , wherein the difference between the amino acid sequence of said BMP9 variant and the amino acid sequence of SEQ ID NO: 4 consists of the substitution D408A.
28. The composition of claim 5 , wherein the difference between the amino acid sequence of said BMP9 variant and the amino acid sequence of SEQ ID NO: 4 consists of the substitution Y418A.